Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Nektar Therapeutics Fourth Quarter 2025 Earnings Call - REZPEG Cleared for Phase 3 After Positive Phase 2s, Cash Buildup to Fund Pivotal Program
Nektar used the call to formalize what its recent data had hinted at, REZPEG is now phase 3 ready after positive phase 2b results in atopic dermatitis and alopecia areata and a deep safety database. M...
- REZPEG demonstrated positive phase 2b results in both atopic dermatitis and alopecia areata, validating the Treg agonist mechanism across dermatologic inflammatory diseases.
- FDA alignment achieved for phase 3 design in atopic dermatitis: 24 microgram per kilogram every two weeks for a 24-week induction, with responders re-randomized to monthly or quarterly maintenance to 52 weeks.
- Phase 3 timeline: first patient randomization expected in June 2026, first pivotal data anticipated mid-2028, and a target BLA submission in 2029.
- +13 more takeaways
Abacus Global Management Q4 2025 Earnings Call - Initiating 2026 Outlook as Fee-Paying AUM Momentum Targets $5B
Abacus closed 2025 with another blowout quarter, its 11th consecutive beat, and a clear push to reframe the story from opportunistic life-policy originator to scaled alternative asset manager. Q4 reve...
- Abacus reported its 11th consecutive quarter beating consensus, Q4 revenue +116% year over year to $71.9 million, and full year 2025 revenue $235.2 million, up 110% versus 2024.
- Management initiated full year 2026 guidance for adjusted net income of $96 million to $104 million, implying up to 22% growth from 2025 adjusted net income of $85.7 million.
- Fee-paying AUM was about $3.3 billion at year-end 2025, management raised the 2026 target to $5 billion in fee-paying AUM by year-end 2026 based on visible inflows and product rollout.
- +12 more takeaways
LivePerson Fourth Quarter 2025 Earnings Call - Syntrix launch aims to unlock enterprise AI spend while 2026 is a transition year with revenue headwinds
LivePerson is trying to turn a year of rebuilding into an execution story. The headline is Syntrix, a newly GAed simulation and assurance platform meant to remove trust barriers for enterprise AI depl...
- LivePerson launched Syntrix to general availability, positioning it as an AI simulation and assurance layer to validate AI agent behavior, enforce governance, and support compliance at enterprise scale.
- Conversation Simulator is the first Syntrix capability, designed to test and identify drift and failures before AI agents reach customers; roadmap includes analytics, governance, auditability, and self-heal features.
- Syntrix is model and platform agnostic, integrates with LivePerson Conversational Cloud, and is intended to work with competing CX and CCaaS platforms to provide a consistent governance layer.
- +12 more takeaways
Runway Growth Finance Q4 2025 Earnings Call - SWK Acquisition to Diversify Portfolio and Stabilize Earnings
Runway used the quarter to sell the narrative that a pending SWK Holdings acquisition is the structural fix investors have been waiting for. Management expects the deal to close in early April, bringi...
- Runway reported Q4 2025 total investment income of $30.0 million and net investment income of $11.6 million, down sequentially as prepayment fee income normalized.
- Management reiterated the SWK Holdings acquisition is expected to close in early April and remains on track, and the company is confident in closing the transaction.
- The SWK transaction will transfer roughly 13 loans with about $235 million in fair value, plus equity positions and royalties, with the total portfolio yield near 14% and the debt-only yield about 16%.
- +13 more takeaways
Health Catalyst Fourth Quarter 2025 Earnings Call - CEO-Led Reset as DOS-to-Ignite Migration Puts $65M ARR at Risk
Health Catalyst closed 2025 with modest top-line progress and a management reset. Full-year revenue was $311.1 million, up 1% year over year, driven by a 7% rise in technology revenue to $208.3 millio...
- Leadership change and strategic reset: Ben Albert named CEO after Dan Burton’s departure, initiating a comprehensive review of product portfolio, cost structure, and go-to-market motion.
- Guidance limited: Company withheld full-year 2026 guidance, providing Q1 2026 revenue guidance of $68M to $70M and Adjusted EBITDA of $7M to $8M only.
- Revenue snapshot: Full-year 2025 revenue $311.1M, up 1% year over year; Q4 2025 revenue $74.7M versus $79.6M year-ago.
- +12 more takeaways
Hallador Energy Company Q4 2025 Earnings Call - ERAS slot secures pathway for gas expansion as accredited capacity prices surge
Hallador closed 2025 with improved profitability and a clear strategic shift toward becoming a vertically integrated independent power producer. Full year revenue rose 16% to $469.5 million, net incom...
- Hallador reported full-year 2025 revenue of $469.5 million, up 16% year-over-year, driven largely by electric sales growth.
- Net income improved materially to $41.9 million for 2025, and adjusted EBITDA increased about threefold to $56 million, showing operating leverage.
- Operating cash flow for 2025 rose 23% to $81.1 million, despite a weaker cash quarter-to-quarter driven by timing of prepaid contract receipts.
- +12 more takeaways
American Outdoor Brands Third Quarter Fiscal 2026 Earnings Call - Reiterated Guidance While Wrestling Tariff Hits, Aiming-Solutions Weakness, and a UST Impairment
American Outdoor Brands reported a mixed Q3: net sales of $56.6 million, down 3.3% year-over-year, but POS momentum and new-product traction underpin management confidence. The company held full-year ...
- Net sales were $56.6 million in Q3 FY26, down 3.3% year-over-year, but above company expectations.
- Point-of-sale grew 5% in the quarter, marking the third consecutive quarter of favorable POS results; management says adjusted sales would be high-single-digit growth when excluding two headwinds.
- Outdoor lifestyle generated 62% of net sales and grew 5.4% year-over-year, driven by BOG and MEAT! Your Maker.
- +12 more takeaways
Mission Produce Q1 FY2026 Earnings Call - Volume Growth Shields Margins as Calavo Deal Targets $25M in Synergies
Mission Produce navigated a sharp industry price reset in Q1 FY2026 by leaning into volume and per unit margin management, posting $278.6 million in revenue, down 17% year over year, while growing avo...
- Q1 revenue $278.6 million, down 17% year over year, driven by a ~30% decline in avocado pricing due to heavier Mexican supply.
- Avocado volumes up 14% in the quarter, underscoring the company’s volume-centric operating approach.
- Gross profit was flat at $31.6 million, while gross margin improved 190 basis points to 11.3% versus prior year.
- +12 more takeaways
SentinelOne Q4 FY2026 Earnings Call - Passed $1B, turned profitable, AI security drives record ARR
SentinelOne closed fiscal 2026 by crossing $1 billion in revenue, delivering full-year operating profitability and a record quarter for net new ARR. Q4 revenue was $271 million (up 20% YoY), total ARR...
- Scaled past $1 billion in revenue for FY2026, delivering 22% year-over-year revenue growth and achieving full-year operating profitability (operating margin 3.5% for FY2026).
- Q4 revenue was $271 million, up 20% YoY; total ARR grew 22% YoY and SentinelOne added a company-record $64 million of net new ARR in Q4.
- Management is pushing an upmarket strategy: customers with ARR >$1M grew to 153 (up 20% YoY), and customers with ARR >$100k reached 1,667 (up 18% YoY).
- +11 more takeaways
Ulta Beauty Q4 FY2025 Earnings Call - Investments Paying Off, Guiding to Profitable Growth and ~$1B Share Buybacks
Ulta closed fiscal 2025 with a clear message, execute then harvest. Sales rose roughly 10% to $12.4 billion, comps were +5.4% for the year and Q4 sales jumped 11.8% to $3.9 billion. Management says he...
- Fiscal 2025 net sales grew 9.7% to $12.4 billion; Q4 net sales rose 11.8% to $3.9 billion.
- Comparable sales were +5.4% for the year and +5.8% in the quarter; Q4 comps benefited from strong holiday execution and easier January compares.
- Full-year diluted EPS was $25.64, up 1.2% year over year; Q4 EPS was $8.01.
- +12 more takeaways